Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.75 |
| ▸ | GAA | P10253 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14418259 | 0.85 | MAPT (0.75) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL10113781 | 0.83 | MAPT (1.00) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL10113752 | 0.79 | MAPT (0.85) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL3394058 | 0.79 | ALDH1A1 (0.71) | MAPTHTTPOLBALDH1A1GAA | |
| SCHEMBL19752716 | 0.79 | ALDH1A1 (0.71) | MAPTHTTPOLBALDH1A1GAA | |
| SCHEMBL29531249 | 0.79 | ALDH1A1 (0.71) | MAPTHTTPOLBALDH1A1GAA | |
| SCHEMBL3395226 | 0.72 | ALDH1A1 (0.67) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL10113794 | 0.71 | ALDH1A1 (1.00) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL392493 | 0.71 | MAPT (0.84) | MAPTHTTNPSR1POLBALDH1A1 | |
| SCHEMBL7437010 | 0.70 | ALDH1A1 (0.77) | MAPTPOLBALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | MAPT 1311/4885HTT 1892/4885NPSR1 401/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | MAPT 1311/4885HTT 1892/4885NPSR1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.